TELA Bio faces a critical inflection point as revenue growth decelerated to 2.9% in 2026Q1, signaling significant friction in its market penetration strategy. The company's reliance on a high-cost direct sales force has resulted in persistent operating losses ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | -$0.20-15.1% vs -$0.17 | $19M-3.6% vs $20M |
Q2 2026 May 12, 2026 | -$0.21-50.0% vs -$0.14 | $19M+2.5% vs $19M |
Q2 2026 Mar 25, 2026 | -$0.16+11.1% vs -$0.18 | $21M-0.8% vs $21M |
Q4 2025 Nov 13, 2025 | -$0.19-11.8% vs -$0.17 | $21M-1.7% vs $21M |
Baxter International (NYSE: BAX - Get Free Report) and TELA Bio (NASDAQ: TELA - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership. Volatility and Risk Baxter International has a beta
Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.22 per share a year ago.
Benchmark TELA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for TELA Bio, Inc. (TELA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.30 | $58.16M | -1.57 | 15.84% | -48.37% | -223.35% | — | |
| $0.38 | $52.6M | 12.50 | 14.21% | -10.17% | -23.45% | — | |
| $59.96 | $3.05B | -249.81 | 14.88% | 1.85% | 2.14% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $3.99 | $274.71M | -4.24 | -38.1% | -43.7% | -14.73% | — | |
| $87.07 | $5.19B | 40.88 | 11.66% | 9.22% | 9.07% | — |
TELA Bio, Inc. (TELA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
TELA Bio, Inc. (TELA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Aug 4, 2026·SEC
Jun 11, 2026·SEC
Get notified when TELA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TELA Bio, Inc. (TELA) stock FAQ — growth, dividends, profitability & financials explained
TELA Bio, Inc. (TELA) reported $79.9M in revenue for fiscal year 2025. This represents a 1782% increase from $4.2M in 2017.
TELA Bio, Inc. (TELA) grew revenue by 15.8% over the past year. This is strong growth.
TELA Bio, Inc. (TELA) reported a net loss of $41.2M for fiscal year 2025.
TELA Bio, Inc. (TELA) has a return on equity (ROE) of -223.4%. Negative ROE indicates the company is unprofitable.
TELA Bio, Inc. (TELA) had negative free cash flow of $31.6M in fiscal year 2025, likely due to heavy capital investments.
